A carregar...
Clinical performance of non-invasive prenatal served as a first-tier screening test for trisomy 21, 18, 13 and sex chromosome aneuploidy in a pilot city in China
BACKGROUND: Cell-free fetal DNA (cffDNA) has opened up new approaches for non-invasive prenatal testing (NIPT), and it is often used as the second-tier test for high-risk pregnant women in detecting trisomy (T) 21, T18, and T13 after serum biochemistry screening. This study aims to discuss the clini...
Na minha lista:
Publicado no: | Hum Genomics |
---|---|
Main Authors: | , , , , , , , , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
BioMed Central
2020
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7275506/ https://ncbi.nlm.nih.gov/pubmed/32503639 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40246-020-00268-2 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|